Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study EGF107671 - a phase II study of lapatinib plus topotecan or lapatinib plus capecitabine in the treatment of recurrent brain metastases from ErbB2 [HER2]-positive breast cancer following cranial radiotherapy.

Next Previous
X
Search
Trial Profile

Study EGF107671 - a phase II study of lapatinib plus topotecan or lapatinib plus capecitabine in the treatment of recurrent brain metastases from ErbB2 [HER2]-positive breast cancer following cranial radiotherapy.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Topotecan (Primary)
  • Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 01 Dec 2011 Results published in the Journal of Neuro-Oncology.
    • 23 Feb 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Planned end date changed from 1 Jul 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top